Phase 3 PTSD Trial, Recruiting NCT04801589 Sponsor: Vanderbilt University Medical Center Condition: PTSD
Back to Ptsd

Phase 3 PTSD Trial, Recruiting

NCT04801589
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children aged from 44 weeks post-menstrual age (a measure used for premature babies) up to 11 years old (confirm with trial site if unsure how age is calculated)
  • Children who are planned to be admitted to the pediatric ICU at Monroe Carell Jr. Children's Hospital at Vanderbilt
  • Children who need a breathing machine (mechanical ventilator) and sedation medication to keep them calm and comfortable

Who may not be able to join:

  • Children who have already been on continuous sedation for more than 72 hours before being assessed for the trial
  • Children whose breathing problems are clearing up quickly and who are expected to be taken off the breathing machine very soon
  • Children who had significant pre-existing cognitive or developmental disability before their current illness, based on a specific medical rating scale (confirm with trial site)
  • Children with certain serious heart rhythm problems or a heart rate below 60 beats per minute
  • Children who are medically dependent on a continuous drip of benzodiazepine (a type of sedation medication)
  • Children who cannot be enrolled alongside another research study at the same time
  • Children who are expected to pass away or have a plan to stop life-sustaining treatment within 24 hours of joining
  • Children with total vision loss in both eyes
  • Children with deafness that would prevent doctors from being able to assess them for delirium (a state of confusion)
  • Children who cannot understand English well enough for delirium testing to be completed — though this may not apply if research staff or translation services are available in the child's language (confirm with trial site)
  • Children with a documented allergy to either of the two study medications: dexmedetomidine or midazolam
  • Children who are expected to need continuous muscle-paralysing medication (neuromuscular blockade) for at least 48 hours at the time of assessment
  • Children whose weight at the time of assessment is above 50 kilograms
  • Cases where the consent process cannot be started within 72 hours of the child first meeting all the eligibility requirements — for example, if the child's legal guardian is unavailable, declines, or does not speak a language that available staff or translators can support

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Heidi Smith, MD, MSCI, Vanderbilt University Medical Center

Phone: (615) 936-6808

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 May 2021
Est. completion
17 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Daily prevalence of delirium

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov